The Wu-Tang Clan rapper has recorded a video smackdown of pharma bad boy Shkreli.» Read More
Eli Lilly CEO John Lechleiter discusses clinical trials of his company's treatments for Alzheimer's disease.
Eli Lilly's John Lechleiter says he's optimistic about the year ahead for the pharmaceuticals industry, including measures to help patients afford prescription drugs.
Liquid biopsies that show genetic mutations of DNA in a person's blood will dramatically improve early detection of cancers.
The JPMorgan Health Care Conference, which kicks off next week, could take on a more muted tone than in previous years.
Martin Shrekli is using a brokerage account to secure his $5 million bond to keep him out of jail as he fights fraud charges.
Growth in 2016 will be driven by innovation in sectors such as pharmaceuticals and biotechs, notes Adam Schor, SVP and director of global equity strategies at Janus Capital.
Valeant Pharmaceuticals on Wednesday named Howard Schiller interim chief executive officer, effective immediately.
CNBC's Meg Tirrell takes a look back on the year in biotechnology and finds one particular fund that outperformed the sector.
Valeant Pharmaceuticals will appoint an interim chief CEO to replace Michael Pearson who is hospitalized, sending shares down 7 percent on Tuesday.
Drugmaker Eli Lilly revised its 2015 earnings estimate lower and forecast 2016 earnings of $2.92 to $3.02 per share.
Check out the companies making headlines after the bell Monday: Kohl's, Activision Blizzard, Yahoo & more.
Richard Kovacevich, former Chairman & CEO, Wells Fargo, shares his thoughts on the controversy over drug testing at the health tech company.
The "Fast Money" traders give their final trades for 2015.
CNBC's Meg Tirrell takes a look at FDA new drug approvals and what biotech will look like in 2016.
Activist investor Bill Ackman has trimmed his stake in embattled drugmaker Valeant Pharmaceuticals.
Activist investor Bill Ackman's Pershing Square Capital Management is cutting its stake in Valeant Pharmaceuticals, reports CNBC's Seema Mody.
Check out the companies making headlines after the bell Wednesday: Chimerix, Weight Watchers, Lockheed Martin & more.
CNBC's Kate Kelly reports on statements made by Point72 to CNBC regarding their stake in Chimerix.
CNBC's Meg Tirrell details Point72's newly disclosed stake in Chimerix.
Global Financial Private Capital Chief Strategist Mike Sorrentino defends biotech companies in the face of drug pricing pressures.
Get the best of CNBC in your inbox